8-K

                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    FORM 8-K

                CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF
                       THE SECURITIES EXCHANGE ACT OF 1934

                                 Date of Report
                (Date of earliest event reported): June 16, 2004

                           ARIAD PHARMACEUTICALS, INC.
             ------------------------------------------------------
             (Exact Name of Registrant as Specified in its Charter)


  Delaware                             0-21696                   22-3106987
 ----------                          -----------               -------------
(State or Other Jurisdiction    (Commission File Number)      (I.R.S. Employer
of Incorporation)                                            Identification No.)


                              26 LANDSDOWNE STREET
                         CAMBRIDGE, MASSACHUSETTS 02139
              (Address of principal executive offices and zip code)


               Registrant's telephone number, including area code:
                                 (617) 494-0400






ITEM 5.    OTHER EVENTS

           On June 16, 2004, the Registrant disseminated a Press Release
           announcing that it will provide a live webcast of its Annual Meeting
           of Shareholders to be held on Wednesday, June 23, 2004, at 10:00 a.m.
           (ET). The webcast will include an overview of the Company and its
           progress in key programs provided by Harvey J. Berger, M.D., chairman
           and chief executive officer of ARIAD.

           The information contained in the Press Release dated June 16, 2004,
           is incorporated herein by reference and attached as Exhibit 99.1
           hereto.

ITEM 7.    FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS.


           (c)    Exhibits.

                  99.1     The Registrant's Press Release dated June 16, 2004.



                                   SIGNATURES

         Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.


                                  ARIAD PHARMACEUTICALS, INC.



                                  By:    /s/ Edward M. Fitzgerald
                                         --------------------------------------
                                         Edward M. Fitzgerald
                                         Senior Vice President and
                                         Chief Financial Officer


Date:    June 16, 2004


                                       2





                                  EXHIBIT INDEX

Exhibit                                                             Sequential
Number     Description                                             Page Number
- -------    -----------                                            --------------

99.1       The Registrant's Press Release dated June 16, 2004.          4


                                       3

EX-99

                                                          EXHIBIT 99.1

ARIAD Announces Webcast of Its Annual Meeting

    CAMBRIDGE, Mass.--(BUSINESS WIRE)--June 16, 2004--ARIAD
Pharmaceuticals, Inc. (Nasdaq: ARIA) today announced that it will
provide a live webcast of its Annual Meeting of Shareholders to be
held on Wednesday, June 23, 2004, at 10:00 a.m. (ET). The webcast will
include an overview of the Company and its progress in key programs
provided by Harvey J. Berger, M.D., chairman and chief executive
officer of ARIAD.
    A direct link to the audio portion of the live presentation can be
accessed at ARIAD's website (http://www.ariad.com/investor) by
clicking on this link. An archived audio webcast also will be
available beginning approximately two hours after completion of the
presentation until 5:00 p.m. (ET) on July 2, 2004. To ensure a timely
connection to the live webcast, it is recommended that participants
register at least fifteen minutes prior to the scheduled webcast.
    ARIAD is engaged in the discovery and development of breakthrough
medicines to treat cancer by regulating cell signaling with small
molecules. The Company is developing a comprehensive approach to
patients with cancer that addresses the greatest medical need -
aggressive and advanced-stage cancers for which current treatments are
inadequate. ARIAD also has an exclusive license to pioneering
technology and patents related to certain NF-(kappa)B treatment
methods, and the discovery and development of drugs to regulate
NF-(kappa)B cell-signaling activity.
    Additional information about ARIAD can be found on the web at
http://www.ariad.com.

    Some of the matters discussed herein are "forward-looking
statements" within the meaning of the Private Securities Litigation
Reform Act of 1995. Such statements are identified by the use of words
such as "anticipate," "estimate," "expect," "project," "intend,"
"plan," "believe," and other words and terms of similar meaning in
connection with any discussion of future operating or financial
performance. Such statements are based on management's current
expectations and are subject to certain factors, risks and
uncertainties that may cause actual results, outcome of events, timing
and performance to differ materially from those expressed or implied
by such forward-looking statements. These risks include, but are not
limited to, risks and uncertainties regarding the Company's ability to
conduct preclinical and clinical studies of its product candidates,
risks and uncertainties that clinical trial results at any phase of
development may be adverse or may not be predictive of future results
or lead to regulatory approval of any of the Company's product
candidates, and risks and uncertainties relating to regulatory
oversight, intellectual property claims, the timing, scope, cost and
outcome of legal proceedings, future capital needs, key employees,
dependence on the Company's collaborators and manufacturers, markets,
economic conditions, products, services, prices, reimbursement rates,
competition and other risks detailed in the Company's public filings
with the Securities and Exchange Commission, including ARIAD's Annual
Report on Form 10-K for the fiscal year ended December 31, 2003. The
information contained in this document is believed to be current as of
the date of original issue. The Company does not intend to update any
of the forward-looking statements after the date of this document to
conform these statements to actual results or to changes in the
Company's expectations, except as required by law.

    CONTACT: ARIAD Pharmaceuticals, Inc.
             Tom Pearson, 610-407-9260
             or
             Kathy Lawton, 617-621-2345